Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Diabetic Nephropathies
- Main trialPhase 2
- “To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.”In the company’s words, NCT05718375 on ClinicalTrials.gov
Other drugs for Diabetic Nephropathies
- WAL0921Walden Biosciences · Phase 2
- R3R01River 3 Renal Corp. · Phase 2
- IsuzinaxibAptabio Therapeutics, Inc. · Phase 2
- Umbilical Cord Mesenchymal Stem CellsPT. Prodia Stem Cell Indonesia · Phase 1/2
- ALN-ANG3Regeneron · Phase 2
- EvinacumabRegeneron · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 12 Nov 2025 | Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026